Additionally, MAE improves hepatic insulin resistance through inhibiting PGC-1α and FOXO1 transcriptional activity to decrease gluconeogenesis as well as suppressing JNK phosphorylation to enhance insulin signalling transduction. The gene discussed is FOXO1; the disease is Insulin resistance.